Summarized by Masters of Longevity from Longevity Technology.
Discussion of emerging regulatory momentum toward recognizing aging-related endpoints, driven by consensus proposals, funders, and industry signals.
Key Takeaways
- Regulator, payer, and federal funder speakers at H-SPAN all identified validated surrogate endpoints as the chief obstacle to aging indications.
- An ARPA-H–linked expert group recommended Intrinsic Capacity composites as near-term, FDA-interpretable geroscience endpoints.
- A Stanford-led THRIVE coalition received up to $34.5 million from ARPA-H PROSPR to build an FDA-grade Intrinsic Capacity score.
